vaccination purposes, is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided efficient uptake and crosspresentation by appropriately activated skin DC can be achieved. Here, we compared i.d. delivery of apoptotic blebs (0.1-1 μm), derived from MART-1 transduced acute myeloid leukemia (AML) HL60 cells, to that of larger apoptotic cell remnants (ACR; 2-10 μm) in a physiologically highly relevant human skin explant model. Injection of either fluorescently labelled ACR or blebs did not affect the number nor the distribution of migrated DC subsets from skin biopsies after 48 hours, but resulted in a general up-regulation of the co-stimulatory molecules CD83 and CD86 on skin DC that had ingested apoptotic material. We previously showed that i.d. administration of GM-CSF and IL-4 resulted in preferential migration of a mature and highly T cell-stimulatory CD11hiCD1a+CD14-dermal DC subset. Co-injection of ACR or blebs resulted in uptake efficiencies in this subset of 7.6 % (± 6.1 %) and 19.1 % (± 15.9 %), respectively, thus revealing a significantly higher uptake of blebs (p<0.02). Intradermal delivery of tumor-derived blebs did not affect the T cell priming and TH skewing abilities of migratory skin DC, but, in contrast to i.d. administration of ACR, did lead to effective cross-presentation of MART-1 to specific CD8+ effector T cells. We conclude that apoptotic bleb-based vaccines delivered through the skin may offer an attractive and broadly applicable tumor immunotherapy.
IN SITU LOADING OF SKIN DENDRITIC CELLS WITH APOPTOTIC BLEB-DERIVED ANTIGENS FOR THE INDUCTION OF TUMOR-DIRECTED IMMUNITY

INTRODUCTION
T he ex vivo culture and loading of dendritic cells (DC) for their preparation as an anti-tumor vaccine is both laborious and costly. Circumventing the need for this by direct administration and in vivo DC targeting of tumor-associated antigens (TAA) is therefore of great interest. The skin is the most commonly used portal for the delivery of anti-tumor vaccines, since a dense network of DC lining the skin is readily accessible and adjuvants can be more safely co-administered as compared to intravenous injection 1 . Migratory dermal DC (DDC) and Langerhans Cells (LC) that reside in the dermis and epidermis respectively, are able to mediate both T and B cell responses in humans 2, 3 . Therefore, targeting skin DC via direct intradermal (i.d.) injection of whole tumor cell vaccines presents an attractive and clinically feasible cancer vaccination methodology. We and others have focused on characterizing human DC subsets present in the skin and draining lymph nodes (LN) [4] [5] [6] [7] . At least four DDC subsets and LC have been identified in the (epi)dermis to date, which can be discriminated by their differential expression profiles of CD1a, CD11c and CD14 (as well as other markers) 4, 8 . Previously, it was shown that intradermal injection of interleukin (IL)-4 and granulocyte macrophage colony stimulating factor (GM-CSF), which are present in the skin under inflammatory conditions, are capable of inducing LC and DDC maturation, as well as LC differentiation [9] [10] [11] . Moreover, injection of IL-4 and GM-CSF in human skin results in the preferential migration of CD1a + CD14 -DDC from human skin explants, and subsequent ex vivo culture has demonstrated that this DDC subset is a potent inducer of T H and CD8 + effector T cells [11] [12] [13] . Indeed, under steady state conditions CD1a + LC and DDC are the most mature DC subsets displaying a T cell stimulatory phenotype 12 . From our previous observations we have concluded that TAA administered via i.d. injection should preferentially target CD1a + CD14 -DDC as these represent the most frequent skin DC subset, with superior T cell activation qualities and thus likely to be the most potent in inducing tumor-specific T cell responses 1, 12, 13 . Tumors have multiple ways of evading immune recognition, one of which is dedifferentiation 14 , accompanied by a loss of TAA expression, suggesting that broadening the tumor-directed immune response by increasing the array of presented TAA is likely to enhance the effectiveness of anti-tumor vaccination strategies. Most immunotherapeutic strategies that target a single TAA, rely on the characterization of TAA, have limited interpatient antigenic overlap and are often HLA-restricted. Using apoptotic whole tumor cell preparations could be instrumental in circumventing these limitations, since it broadens the presented array of TAA, can be patient-specific (provided that there is access to sufficient autologous tumor material) and overcomes HLA restriction. Moreover, novel T cell epitopes (both HLA class I and class II) that are continually being mapped within known TAA antigens 15, 16 , are included in whole apoptotic tumor cell preparations and thus further increase the number of targeted antigens and enhance therapy efficacy. Finally, with a growing recognition of the immunogenicity of neo-epitopes specific to each tumor's individual mutanome 17 , autologous tumor-based vaccines deserve renewed attention as a means of effective personalized immunotherapy.
Apoptosis is a tightly regulated process [18] [19] [20] , during which microvesicles are shed, referred to as blebs (0.1 -1 μm). Blebs have been shown to induce DC maturation in mice 21 , and importantly, in cross-priming experiments, we have shown that monocytederived DC (MoDC) loaded with blebs, more efficiently cross-present TAA to CD8 + T cells as compared to MoDC loaded with larger apoptotic cell remnants (ACR; 2 -10 μm) 22 . Most reported studies assessing the pre-clinical efficacy of whole apoptotic tumor cell vaccines lack detailed descriptions of apoptotic cell/body isolation, and since the isolation of these microvesicles requires an additional centrifugation and isolation step, the fraction enriched for the larger ACR, also referred to as apoptotic bodies, are used in most, if not all, previous studies. The loading of DC with ACR has been described to induce tolerance and to impair DC function [23] [24] [25] , thus necessitating the use of powerful immune stimulatory adjuvants. These findings led us to investigate whether isolated blebs could be a preferred source of TAA over ACR for the induction of tumor-directed immunity through dermal vaccination. To this end, we analyzed the ingestion of both ACR and blebs by human DDC and LC in situ, and their subsequent ability to activate (antigen-specific) T cells post-migration in vitro, using a near-physiological human skin explant model 11, 19 .
RESULTS
Administration of ACR or blebs does not affect the absolute number and subset distribution of migrated skin DC
It was previously demonstrated that i.d. administration of IL-4 and GM-CSF (4/GM) led to maturation and increased migration of LC and DDC from cultured skin explants 11, 27 . We analyzed the effects on the absolute number of cells migrating from the skin explants, after administration of ACR or blebs in the absence or presence of 4/GM. As expected, co-administration of 4/GM led to an increase in the migration of the absolute number of DC in all conditions (Fig. 1A) . Co-injecting either ACR or blebs did not affect the absolute number of egressed DDC in absence or presence of 4/GM. Skin-emigrated DC subsets were discriminated post-migration, by the analysis of CD11c, CD1a and CD14 expression using flow cytometry (Fig. 1B) . We determined the effects on the distribution of the migrated DC subsets after injecting ACR or blebs (Fig. 1C) . Co-injecting blebs in plain medium induced a minor but significant increase in the relative migration of CD1a + CD14 + 5 CHAPTER 5 DDC, compared to injection of plain medium or ACR respectively, but this effect was abrogated after co-administration of 4/GM (Fig. 1C) . The increased and preferential migration of CD1a + CD14 -DDC and LC by i.d. administration of 4/GM, which was consistent with previous observations 12 , was not affected by co-injection of either ACR or blebs (Fig.  1C ). 
CHAPTER 5
Blebs are taken up more efficiently by DDC after co-administration of IL-4 and GM-CSF
In order to analyze the ability of skin-emigrated DC to ingest apoptotic cell material in situ, we injected CFSE-labeled ACR or blebs and analyzed the egressed DC subsets by flow cytometry for CFSE positivity, as a measure of uptake ( Fig. 2A) . Next, we quantified the CFSE positive cells per subset as a percentage of the total fraction of migrated CD11c positive DC, as well as the percentage within a given subset ( Fig. 2B and 2C, respectively). When injected in plain medium, both apoptotic cell fractions were taken up by all DC subsets to some extent (mean 12.9 % ± 11.6 % see Fig. 2B ). Interestingly, co-administration of 4/GM led to an increase in the uptake of apoptotic blebs over the entire range of DC subsets (Fig. 2E ). Most notably, co-administration of 4/GM led to a significant increase in the uptake of blebs over ACR by the CD14 + DDC subsets ( Fig. 2E ), indicative of their superior endocytic capacity, although they numerically represented a minority under these i.d. cytokine conditions (Fig. 2D ). Most importantly, blebs were also ingested by a significantly higher percentage of the predominant migratory CD1a + CD14 -DDC subset (mean 19.1 % ± 15.9 %) as compared to ACR (mean 7.6 % ± 6.1 %; Fig. 2E ). Indeed, CFSE positive CD1a + CD14 -DDC constituted on average 13.0% (± 12.1 %) of the total skin-egressed DC after i.d. injection of blebs, as compared to 5.1% (± 4.5 %) after injection of ACR (Fig. 2D ).
Increased maturation of DDC after ingestion of ACR or blebs
To determine whether the ingestion of apoptotic material (in the presence of 4/GM) by skin-emigrated DC led to alteration in the expression of maturation markers, we analyzed the expression of CD83 and CD86. Surprisingly, ingestion of apoptotic material by LC led to a significant increase in CD86 expression, but coincided with a significant down-regulation of CD83. In contrast, the expression of both CD86 and CD83 on CD1a + CD14 -DDC was increased when this subset had taken up either ACR or blebs. (Fig.  3) . Ingestion of apoptotic material by CD1a -CD14 -led to minor changes in the expression of co-stimulatory molecules and only CD86 expression was significantly increased after ingestion of blebs (Fig. 3) . Encouragingly, uptake of both ACR and blebs by CD1a -CD14 + DDC also led to a significant increase in both CD83 and CD86 expression on this otherwise immature and potentially suppressive subset.
i.d. bleb or ACR administration does not interfere with T cell induction and cytokine profiles
The effect on the cytokine balance in the dermal milieu after i.d. injection of ACR or blebs was determined by analyzing the skin explant culture medium for the presence of the inflammation-related cytokines IL1β, IL-6, IL-8, IL-10, IL12p70 & TNFα, 48 to 72 hours after injection. Although we were able to detect all measured cytokines to a larger or lesser extent (with the exception of TNFα), we observed no significant differences after intradermal delivery of ACR or blebs, either in plain medium or supplemented with 4/ GM (data not shown). After i.d. injection of either ACR or blebs in 4/GM supplemented medium, skin DC that egressed from the biopsies were co-cultured for 6 days with CFSElabeled allogeneic peripheral blood lymphocytes, in order to analyze their capacity to prime T cell responses (measured by CFSE dilution as a measure of T cell proliferation). Our results showed that the ability of the migrated DC to induce either CD4 + or CD8 + T cells was unaffected by i.d. injection of either blebs or ACR (Fig. 4A) , nor was their TH skewing ability, as determined by the analysis of T cell cytokine release (IL-2, IL-4, Il-6, IL-10, IL-17a, IFNγ and TNFα) after 6 days of co-culture (data not shown).
Dermal delivery of blebs leads to effective cross-presentation by migratory DC
Next, we set out to assess the ability of skin-emigrated DC to cross-present antigens derived from blebs or ACR. To this end, either MART-1-transduced or wild type HL60- or K562-derived ACR or blebs were i.d. injected in skin explants from HLA-A2 positive donors in the presence of 4/GM, and skin DC were harvested after 48-72 hours. After a subsequent 24 hours of co-culture with a MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] recognizing CTL line (HLA-A2 restricted; >95% pure), the supernatant was analyzed for the presence of IFNγ, as a measure of cross-presentation of the MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] epitope by egressed DC. The MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] specific IFNγ production was assessed by deducting the IFNγ production following a coculture with DC from wild type ACR or blebs injected skin, from that after co-culturing with DC from MART-1-transduced ACR or blebs (∆ IFNγ, Fig. 4b ). In three separate donors we found the IFNγ production after co-culture with skin DC migrated from bleb-injected skin explants to be 2-to 3-fold elevated as compared to DC egressing from ACR-injected skin (on average ∆ 258 pg/ml vs. ∆ 65 pg/ml, see Fig. 4B ). Moreover, in all donors the IFNγ production after injecting MART-1-containing blebs was at least 2-fold increased over the IFNγ production when injecting wild type blebs (mean 13.2 fold increased), whereas this was the case in only one donor following ACR injection (mean 4.7 fold increased, see Fig.4b ). We were able to confirm these findings in two additional HLA-A2 positive donors, using a MART-1 CTL clone 28 ( Fig. 4C) and by intracellular IFNγ staining on the MART-1 CTL line (Fig. 4C) . Moreover, we could demonstrate expansion of the MART-1 CTL following a co-culture with skin DC that egressed from the biopsies injected with blebs, as compared to DC from medium or ACR-injected skin (Fig. 4c) .
DISCUSSION
The involvement of the immune system in controlling leukemia as well as solid tumors has been well established, and shaping of immune responses to target (residual) tumor cells is a goal pursued in immunotherapy for the last decades. The induction of tumor-directed immunity by means of DC vaccination is intensely studied, but the ex vivo generation of clinical grade DC and the subsequent loading with tumor-associated antigens is costly and laborious, which hinders wide-spread clinical application of DC-based vaccination strategies. Moreover, there is growing evidence that, in order to eradicate tumors and prevent relapse, multiple TAA should be targeted 29 . Previously, we reported on apoptotic cell derived blebs as a potent source of TAA for ex vivo generated DC based vaccines 22 , and hence we explored the relative efficiency of loading skin resident DC with either ACR or blebs in situ, using a human skin explant model, as a tumor cell-based vaccine delivery method. We found i.d. injected blebs to be more efficiently taken up by cytokineactivated skin-resident and migratory DC. Moreover, upon migration of these DC from the skin, TAA derived from blebs were more efficiently cross-presented to CD8 + effector T cells than those derived from i.d. injected ACR. These observations support the dermal 5 CHAPTER 5 delivery of bleb-based vaccines as a means of inducing a broad tumor-reactive T cell response.
In order for antigen-specific T cell nduced after i.d. administration of a apoptotic cell-based vaccine, it is essential that antigen is taken up by DDC or LC (both able to induce T and B cell responses 2, 3 ). The capacity of human DDC to ingest apoptotic material after ex vivo culture has been demonstrated previously 30 , and furthermore LC have been demonstrated to engage apoptotic keratinocytes 31 . Studies administering apoptotic cells for vaccination purposes have suggested apoptotic cells to be taken up by skin resident DC, but to our knowledge this is the first demonstration that i.d. injected apoptotic material is taken up by migratory human DDC and LC. Interestingly, and in contrast to the dogma of reduced exogenous antigen uptake after inducing DC maturation, we observed enhanced uptake of blebs by all migratory DC subsets after co-administration of 4/GM, whereas the uptake was unaffected or even decreased by this cytokine cocktail when ACR were injected. As CD1a + CD14 -DDC constitute the predominant subset migrating from the skin after administration of 4/GM and was previously identified as the most potent in terms of effector T cell activation 11, 12 , preferential uptake of blebs by this subset may prove favorable in terms of vaccination efficacy. It has recently been described that CD14 + DDC are far less potent in effectively priming CD8 + T cells to differentiate into cytotoxic effector cells, as compared to CD1a + DDC and LC, and moreover induce regulatory T cells, a process driven by the production of IL-10 and the expression of Ig-like transcript inhibitory receptors [32] [33] [34] . Interestingly, next to the predominant migration of CD1a + DDC and a significant increase in uptake by this potent DDC subset, injecting 4/GM greatly diminished the migration of CD14 + DDC as compared to injecting plain medium (7.4% vs 25.1% respectively; p = 0.005), confirming our previous observations 11, 12 . Effective T cell priming requires skin DC to migrate from the skin to the draining lymph nodes (LN) after the ingestion of exogenous antigen. Whether the observed migration from the skin explants represents migration towards the LN is unclear, but we and others have shown that CD1a + skin DC express the LN homing chemokine receptor CCR7 and that migrated LC and CD1a + DDC are potent activators of T cells in vitro 11, 13, 32 . Moreover, both these skin-derived DC subset have been identified in skin-draining lymph nodes 4 . Injection of either ACR or blebs (and subsequent ingestion) did not impair skin DC migration from the skin explants, nor their ability to subsequently activate T cells in vitro. Importantly, we demonstrated that MART-1 from blebs was efficiently crosspresented to MART-1 specific CD8 + cytotoxic T cells, whereas MART-1 from ACR was crosspresented to a far lesser extent. Moreover, we showed a clear expansion of the MART-1 CTL following induction with DC that egressed from bleb-injected skin. Clearly, this is a strong argument for the preferred use of blebs over ACR as tumor vaccine.
The increased uptake of blebs compared to ACR, and thereby the higher number of MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] presenting skin DC, is unlikely to be solely responsible for the selective activation of the TAA-specific CD8 + CTL in view of the relatively modest difference in uptake rates of 9.2% vs. 14.8%, respectively. It is known that heat shock proteins, previously described to be present at high levels in apoptotic blebs 35 , greatly facilitate crosspresentation 36 . These could therefore have been responsible for this observed enhancing effect on cross-presentation. An alternative mechanism underlying the increased crosspresentation potential of blebs is the presence of defective ribosomal products, which are present in the endoplasmic reticulum (an organelle actively translocated into blebs 20 ) and are described to be efficiently cross-presented 37, 38 , although we currently have no data to support this hypothesis. In any case, bleb-derived antigen is clearly efficiently ingested and cross-presented by skin DC and direct i.d. administration of tumor-derived blebs can therefore be regarded as a potent immunotherapeutic strategy. Tumors create immune suppressive (micro)environments, which is evident by the preferential migration of CD14 + DDC from explants taken from the skin proximate to the tumor of breast cancer patients 12 . This effect is most likely mediated by IL-10; co-culture of IL-10-conditioned skin emigrated DC with T cells, leads to a diminished T cell proliferation, T H 2 skewing, an increase in regulatory T cells and a reduced priming of functional cytotoxic T cells 12, [32] [33] [34] . The negative modulation of the skin surrounding the tumor area, or even systemically under advanced metastatic conditions, can thereby hamper i.d. vaccination strategies (39) .Counteracting this negative regulation is likely to be crucial, and can be accomplished by co-administering GM-CSF alone 40 , or combined with IL-4 11 . Moreover, CpG and/or Toll-like receptor (TLR) ligands (especially peptidoglycan, a TLR2 ligand) have shown to greatly enhance the human skin DC maturation state and T cell activating properties 27, 41 . Next to creating a beneficial milieu for inducing tumor-directed immunity, specific or enhanced targeting of TAA to DC has shown beneficial effects, e.g. by conjugating TAA to TLR ligands 42 , or generating antibody-antigen complexes 43 . These strategies may also be applied to apoptotic bleb-based vaccines.
Standard therapy of patients with advanced leukemia and other types of cancer often consists of chemotherapeutic regimens. Since the skin can be affected by chemotherapy, there is a possibility that skin DC are affected as well, in which case the vaccination efficacy of direct administration of blebs in the skin is likely to be hampered. Whether this occurs and the kinetics of DC reconstitution in the skin after chemotherapy or, in the case of leukemia, hematopoietic stem cell transplantation (HSCT), remain largely unclear. However, a small number of studies has analyzed the presence of DC in the skin after chemotherapeutic conditioning, demonstrating that DC can be detected in the skin even at early time points (18 days) 44, 45 . Moreover, we have reported improved migration of activated DC and normalized distribution of migrating cutaneous DC subsets (i.e. predominant migration of mature CD1a + DDC and reduced migration of 5 CHAPTER 5 immature macrophage-like CD14 + DDC) after neoadjuvant chemotherapy in patients with breast cancer 12 . These data suggest that it is indeed possible to target skin DC within approximately three weeks following chemotherapy and HSCT. In an autologous setting, vaccination using blebs will be mainly applicable for the treatment of leukemias, as tumor cells are readily available in large numbers in the bone marrow and blood. However, in an allogeneic setting bleb-based vaccines could also be applied to solid tumors (e.g. by generating blebs from cell lines).
In conclusion, we have demonstrated that i.d. administered apoptotic cellderived blebs are ingested efficiently by mature skin DC subsets, which subsequently retain their ability to migrate from the skin, efficiently cross-present TAA, and support subsequent priming and expansion of effector T cells without detrimental skewing of the cell-mediated response. By co-administering immune stimulatory agents (e.g., 4/ GM, CpG, and TLR ligands) tumor-enforced immune suppression can be counteracted and the T cell stimulatory capacity of skin DC can be greatly enhanced 11, 12, 27, 46 . The data presented here, combined with our previous data 22 , present a strong case for the use of blebs as potent source of TAA for the induction of tumor-directed immunity through dermally applied vaccines. 22 . MART-1 expressing HL60 (HLA-A2 -, HLA-A3 + ), or K562 chronic myeloid leukemia (HLA class I negative) cell lines were generated by retroviral transduction of LZRS-MART-1-IRES-∆NGFR, also as previously reported 28 . The MART-1 expressing cells were spun down at 500 x G for 5 minutes, resuspended at 5 * 10 6 cells/ml in RPMI 1640 (Gibco, Paisley, UK), after which apoptosis was induced by incubating the cells for 2 hours at 42°C, as previously described 47 . Next, the cells were irradiated at 50 Gy, washed, and resuspended at 2 * 10 6 per ml in RPMI containing 10% FCS, 100 IU/ml penicillin and 100 μg/ml streptomycin (all Gibco, Paisley, UK). After 72 hours of culture at 37°C and 5% CO 2 , ACR were pelleted by centrifugation at 600g and 4 ˚C for 10 minutes, after which the apoptotic blebs were isolated from the resulting supernatant by centrifugation at 4,000g at 4 ˚C for 10 minutes. ACR and blebs were washed twice with PBS, after which the protein concentration was determined; the fractions were lysed using 5 cycles of sonication (5 second pulse, followed by 5 seconds rest) at 18 micron (Sanyo MSE Soniprep 150, Amsterdam, The Netherlands) and the protein concentration was determined using a ND-1000 Nanodrop spectrophotometer (Thermo Fisher Scientific, Breda, The Netherlands). The apoptotic cell fractions were frozen for future use. Prior to usage, ACR and blebs were thawed and washed twice with PBS (with all centrifugation steps at 600g and 4000g for ACR and blebs respectively), after which the fractions were resuspended at an equivalent protein concentration and used directly, or fluorescently labeled with 1 μM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, Breda, The Netherlands) according to the manufacturer's protocol, and washed with IMDM (Gibco) containing 10% FCS, and subsequently with plain IMDM. The preparations were resuspended and 40 μg protein equivalent was injected per skin explant (20 μl per explant), either in plain IMDM or IMDM supplemented with GM-CSF (100 ng/biopsy; Berlex Laboratories Montville, NJ), and IL-4 (10 ng/biopsy; R&D Systems, Minneapolis, MN).
Skin explants and dermal dendritic cell subset analysis
Human abdominal skin explants were obtained after informed consent from patients undergoing corrective breast or abdominal plastic surgery at the Tergooi hospital (Hilversum, The Netherlands) and used in an anonymous fashion in accordance with the "Code for Proper Use of Human Tissues" as formulated by the Dutch Federation of Medical Scientific Organizations (www.fmwv.nl) and following procedures approved by the institutional review board. Skin samples were used within 24 hours after surgery. Per explant, a volume of 20 μl was injected i.d. using a BD Micro-Fine insulin syringe (0.33-mm (29G) _12.7-mm needle). 6 mm punch biopsies were taken from the 5 mm injection sites (20 -25 explants were taken per condition). Explants were lifted from the skin specimen, cut from the hypodermis, and subsequently cultured in IMDM containing 50 U/ml penicillin-streptomycin, 1.6 mM L-glutamine, and 5% heat-inactivated normal human pooled serum (referred to as skin medium). After 48 to 72 hours the spontaneously migrated cells were harvested, counted and used for subsequent experiments. The biopsy culture medium was frozen and stored for cytokine analysis. Cytokines in the biopsy culture medium were analyzed using an inflammation cytokine bead array (BD Biosciences, Breda, The Netherlands), following manufacturer's protocol. Cells that had egressed from the biopsies were stained as previously described11 for CD11c APC, CD1a PE, CD14 PerCP, CD83 PC7, CD86 V450 (all BD Pharmingen) and analyzed using a BD LSRFortessa™ flow cytometer and BD FACSDiva™ software version 6.3 (BD Biosciences). Migrated DC were cultured with 1 μM CFSE-labeled allogeneic peripheral blood 5 CHAPTER 5 lymphocytes at stimulator to effector ratios of 1:10 for 6 days, at which time T cell cytokines were analyzed in the supernatant using a T H 1/T H 2/T H 17 cytokine bead array (BD Biosciences, Breda, The Netherlands), following the manufacturer's protocol. T cell proliferation was analyzed by labeling the isolated cells with CD3, CD4, and CD8 (BD biosciences), and determining the CFSE dilution of viable T cells on a BD LSRFortessa™ flow cytometer using BD FACSDiva™ software (BD Biosciences).
Antigen cross-presentation
We generated a CTL line recognizing MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in an HLA-A2-restricted fashion (>95% pure by dextramer staining), by priming CD8 + T cells from healthy donors with MART-1 26-35(27L) peptide-loaded JY cells and subsequent sorting and expansion of the specific cells using a MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] dextramer (Immudex). Skin explants were HLA-A2 typed by taking 5 biopsies at the day of surgery, which were cultured in skin medium. After overnight culture, migrated cells were harvested, stained using a FITC-labeled anti-HLA-A2 antibody (MBL International, Des Plaines, Unites States), and subsequently analyzed using a BD LSRFortessa™ flow cytometer. Skin explant-emigrated HLA-A2-matched DC were co-cultured with the CFSE-labeled MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] CTL line (resting). After 24 hours the supernatant was isolated and analyzed for the production of IFNγ using a cytokine bead array (BD Biosciences). After 6 days of co-culture, proliferation was assessed by determining the CFSE dilution on a BD LSRFortessa™ flow cytometer using BD FACSDiva™ software (BD Biosciences).
Statistical analysis
Statistical analysis was performed using GraphPad Prism for Windows version 5 (Graphpad Software inc.). Statistical significance of the ingestion of either ACR or blebs was determined using a paired two-tailed Student's t-test. Multiple group analysis was performed using one-way repeated measures ANOVA, with a Tukey's multiple comparison test. P-values ≤ 0.05 were regarded as significant.
